FibroGen, Inc. (FGEN)

NASDAQ: FGEN · IEX Real-Time Price · USD
2.120
+0.270 (14.59%)
Feb 27, 2024, 4:00 PM EST - Market closed
14.59%
Market Cap 209.96M
Revenue (ttm) 147.75M
Net Income (ttm) -284.23M
Shares Out 98.34M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE 61.35
Dividend n/a
Ex-Dividend Date n/a
Volume 3,137,302
Open 1.610
Previous Close 1.850
Day's Range 1.580 - 2.220
52-Week Range 0.333 - 23.530
Beta 0.70
Analysts Sell
Price Target 10.00 (+371.7%)
Earnings Date Feb 26, 2024

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical developm... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2014
Employees 592
Stock Exchange NASDAQ
Ticker Symbol FGEN
Full Company Profile

Financial Performance

In 2023, FibroGen's revenue was $147.75 million, an increase of 4.99% compared to the previous year's $140.73 million. Losses were -$284.23 million, -3.21% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for FGEN stock is "Sell." The 12-month stock price forecast is $10.0, which is an increase of 371.70% from the latest price.

Price Target
$10.0
(371.70% upside)
Analyst Consensus: Sell
Stock Forecasts

News

FibroGen regains rights to anemia drug from AstraZeneca

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

Other symbols: AZN
1 day ago - Reuters

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

•   Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 •   Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate ...

1 day ago - GlobeNewsWire

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (N...

1 day ago - GlobeNewsWire

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen...

7 days ago - GlobeNewsWire

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. ...

22 days ago - GlobeNewsWire

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN...

4 weeks ago - GlobeNewsWire

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of l...

2 months ago - Business Wire

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5...

2 months ago - GlobeNewsWire

FibroGen Reports Third Quarter 2023 Financial Results

SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company's recent developments.

4 months ago - GlobeNewsWire

FibroGen to Report Third Quarter 2023 Financial Results

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also c...

4 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...

5 months ago - Accesswire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, In...

5 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, In...

5 months ago - Accesswire

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystrophy failed to meet its primary and secondary endpo...

6 months ago - Market Watch

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline...

6 months ago - GlobeNewsWire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...

6 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...

6 months ago - Accesswire

FibroGen Reports Second Quarter 2023 Financial Results

SAN FRANCISCO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2023 and provided an update on the Company's recent developments.

7 months ago - GlobeNewsWire

FibroGen Announces Leadership Transition

Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- ...

7 months ago - GlobeNewsWire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...

7 months ago - Accesswire

FibroGen to Report Second Quarter 2023 Financial Results

SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also co...

7 months ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...

7 months ago - Accesswire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...

7 months ago - Accesswire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AADIINGNSILKTHRX
8 months ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to cont...

8 months ago - PRNewsWire